Regulation of bradykinin action at the receptor level. 1990

A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
Dr. von Haunerschen Kinderspital der Universität München, Abteilung für Klinische Biochemie, F.R.G.

Intact cultured human foreskin fibroblasts can be used as an in vitro system to study the regulatory events related to kinin receptor function. Specific bradykinin (BK) receptor sites (B2 subtype) were measured by direct binding study and correlated with BK-induced biological effects such as the release of inositol phosphates, formation of prostacyclin (PGI2), and accumulation of cyclic 3'5' adenosine monophosphate (cAMP). Depending on the ambient concentration of BK in the culture medium, homologous receptor downregulation accompanied by a reduction in BK-stimulated PGI2 release occurred. These events were transient and followed by the recovery of both BK binding sites and BK responsiveness that was related to destruction of BK by highly active degradation systems. The fate of receptor-bound [3H]BK was studied by the acetic acid "stripping technique" that completely removes surface-bound [3H]BK while leaving internalized material with the remaining cells. Kinetic analysis of inside/surface ratios of 3H radioactivity revealed data consistent with the hypothesis of internalization of BK-receptor complexes. High-performance liquid chromatography (HPLC) analysis of internalized 3H counts showed significant quantities of intact [3H]BK occurring in an intracellular compartment. Compounds or drugs that enhance intracellular cAMP levels or inhibit generation of eicosanoids were shown to modify the BK response by indirect means. BK-receptor binding sites appear to be under tight regulatory control by both the mechanisms influencing the ambient concentration of BK and the interaction between multiple mediators.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010716 Phosphatidylinositols Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to the hexahydroxy alcohol, myo-inositol. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid, myo-inositol, and 2 moles of fatty acids. Inositide Phospholipid,Inositol Phosphoglyceride,Inositol Phosphoglycerides,Inositol Phospholipid,Phosphoinositide,Phosphoinositides,PtdIns,Inositide Phospholipids,Inositol Phospholipids,Phosphatidyl Inositol,Phosphatidylinositol,Inositol, Phosphatidyl,Phosphoglyceride, Inositol,Phosphoglycerides, Inositol,Phospholipid, Inositide,Phospholipid, Inositol,Phospholipids, Inositide,Phospholipids, Inositol
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D001920 Bradykinin A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg,Bradykinin Acetate, (9-D-Arg)-Isomer,Bradykinin Diacetate,Bradykinin Hydrochloride,Bradykinin Triacetate,Bradykinin, (1-D-Arg)-Isomer,Bradykinin, (2-D-Pro)-Isomer,Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (2-D-Pro-7-D-Pro)-Isomer,Bradykinin, (3-D-Pro)-Isomer,Bradykinin, (3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (5-D-Phe)-Isomer,Bradykinin, (5-D-Phe-8-D-Phe)-Isomer,Bradykinin, (6-D-Ser)-Isomer,Bradykinin, (7-D-Pro)-Isomer,Bradykinin, (8-D-Phe)-Isomer,Bradykinin, (9-D-Arg)-Isomer,Arg Pro Pro Gly Phe Ser Pro Phe Arg
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D005246 Feedback A mechanism of communication within a system in that the input signal generates an output response which returns to influence the continued activity or productivity of that system. Feedbacks
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast

Related Publications

A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
October 1979, Life sciences,
A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
January 1983, Psychoneuroendocrinology,
A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
January 1991, Journal of internal medicine. Supplement,
A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
November 1963, Comptes rendus des seances de la Societe de biologie et de ses filiales,
A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
June 1996, The American journal of physiology,
A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
October 1990, The Proceedings of the Nutrition Society,
A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
August 1997, British journal of pharmacology,
A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
March 2021, Journal of integrative neuroscience,
A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
July 1997, Molecular pharmacology,
A A Roscher, and C Klier, and R Dengler, and A Faussner, and W Müller-Esterl
June 1991, British journal of pharmacology,
Copied contents to your clipboard!